LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist B in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset - HMS LINCS Database

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist B in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20359)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 11 of 67
Next
>>
>
251 to 275 of 1656 records
per page:

Small Molecule	barcode	cell_count	frac_dead	corpse_count	cell_count_dead	row	column	agent	concentration	role	timepoint	replicate	cell_line	dead_count	fraction_dead	cell_count__time0	dead_count__time0	cell_count__ctrl	dead_count__ctrl	fraction_dead__ctrl	increase_fraction_dead	GRvalue
Dasatinib	180622_BG_7	4842	0.0888	55	380	6	12	Dasatinib	0.997999808	treatment	72	2	MCF10A-GM_4	435	0.0824	832.0	168.3	20016	537.9	0.0261	0.05631	0.4679
Dasatinib	180622_BG_6	1508	0.1889	59	237	7	20	Dasatinib	3.193598006	treatment	72	2	MCF10A-GM_1	296	0.1641	832.0	168.3	20016	537.9	0.0261	0.13795	0.1384
Dasatinib	180622_BG_6	7246	0.0416	80	225	12	12	Dasatinib	0.316033316	treatment	72	2	MCF10A-GM_3	305	0.0404	832.0	168.3	20016	537.9	0.0261	0.01427	0.6027
Dasatinib	180614_BG_03	10091	0.0267	101	171	3	16	Dasatinib	0.099799999	treatment	72	1	MCF10A-GM_4	272	0.0262	889.0	105.5	17054	348.0	0.0200	0.00625	0.7683
Dasatinib	180622_BG_7	6174	0.0518	58	265	4	20	Dasatinib	0.316033316	treatment	72	2	MCF10A-GM_4	323	0.0497	832.0	168.3	20016	537.9	0.0261	0.02359	0.5478
Dasatinib	180614_BG_02	11130	0.0178	29	170	6	16	Dasatinib	0.099799999	treatment	72	1	MCF10A-GM_3	199	0.0176	889.0	105.5	17054	348.0	0.0200	-0.00243	0.8094
Dasatinib	180622_BG_6	6772	0.0457	80	233	10	20	Dasatinib	0.316033316	treatment	72	2	MCF10A-GM_2	313	0.0442	832.0	168.3	20016	537.9	0.0261	0.01805	0.5793
Dasatinib	180622_BG_7	6610	0.0386	76	182	9	17	Dasatinib	0.316033316	treatment	72	2	MCF10A-GM_5	258	0.0376	832.0	168.3	20016	537.9	0.0261	0.01144	0.5709
Dasatinib	180622_BG_8	12297	0.0276	72	269	6	3	Dasatinib	0.099799999	treatment	72	2	MCF10A-GM_8	341	0.0270	832.0	168.3	20016	537.9	0.0261	0.00086	0.7985
Dasatinib	180622_BG_8	12636	0.0247	69	245	12	8	Dasatinib	0.099799999	treatment	72	2	MCF10A-GM_9	314	0.0242	832.0	168.3	20016	537.9	0.0261	-0.00188	0.8092
Dasatinib	180614_BG_02	10928	0.0258	77	207	6	6	Dasatinib	0.099799999	treatment	72	1	MCF10A-GM_2	284	0.0253	889.0	105.5	17054	348.0	0.0200	0.00533	0.8017
Dasatinib	180614_BG_02	9659	0.0255	27	220	5	17	Dasatinib	0.099799999	treatment	72	1	MCF10A-GM_1	247	0.0249	889.0	105.5	17054	348.0	0.0200	0.00494	0.7502
Dasatinib	180622_BG_6	6759	0.0481	85	244	8	14	Dasatinib	0.316033316	treatment	72	2	MCF10A-GM_1	329	0.0464	832.0	168.3	20016	537.9	0.0261	0.02029	0.5786
Dasatinib	180622_BG_7	6185	0.0461	47	240	12	9	Dasatinib	0.316033316	treatment	72	2	MCF10A-GM_6	287	0.0443	832.0	168.3	20016	537.9	0.0261	0.01822	0.5484
Dasatinib	180622_BG_7	10819	0.0343	100	275	5	11	Dasatinib	0.099799999	treatment	72	2	MCF10A-GM_5	375	0.0335	832.0	168.3	20016	537.9	0.0261	0.00738	0.7490
Dasatinib	180622_BG_7	10869	0.0262	58	228	10	6	Dasatinib	0.099799999	treatment	72	2	MCF10A-GM_6	286	0.0256	832.0	168.3	20016	537.9	0.0261	-0.00049	0.7508
Dasatinib	180614_BG_04	15301	0.0242	179	195	3	17	Dasatinib	0.033266667	treatment	72	1	MCF10A-GM_8	374	0.0239	889.0	105.5	17054	348.0	0.0200	0.00386	0.9497
Dasatinib	180614_BG_04	15338	0.0274	168	257	3	8	Dasatinib	0.033266667	treatment	72	1	MCF10A-GM_7	425	0.0270	889.0	105.5	17054	348.0	0.0200	0.00697	0.9508
Dasatinib	180614_BG_04	16850	0.0209	128	226	9	9	Dasatinib	0.033266667	treatment	72	1	MCF10A-GM_9	354	0.0206	889.0	105.5	17054	348.0	0.0200	0.00058	0.9944
Dasatinib	180614_BG_03	14695	0.0177	72	189	8	18	Dasatinib	0.033266667	treatment	72	1	MCF10A-GM_6	261	0.0175	889.0	105.5	17054	348.0	0.0200	-0.00254	0.9313
Dasatinib	180622_BG_8	11523	0.0321	90	283	4	4	Dasatinib	0.099799999	treatment	72	2	MCF10A-GM_7	373	0.0314	832.0	168.3	20016	537.9	0.0261	0.00523	0.7732
Dasatinib	180622_BG_8	6893	0.0610	91	335	3	5	Dasatinib	0.316033316	treatment	72	2	MCF10A-GM_7	426	0.0582	832.0	168.3	20016	537.9	0.0261	0.03208	0.5854
Dasatinib	180622_BG_6	1778	0.1612	65	232	12	3	Dasatinib	3.193598006	treatment	72	2	MCF10A-GM_2	297	0.1431	832.0	168.3	20016	537.9	0.0261	0.11701	0.1800
Dasatinib	180622_BG_6	1758	0.1826	109	232	13	9	Dasatinib	3.193598006	treatment	72	2	MCF10A-GM_3	341	0.1625	832.0	168.3	20016	537.9	0.0261	0.13633	0.1771
Dasatinib	180622_BG_8	16635	0.0302	61	443	3	8	Dasatinib	0.033266667	treatment	72	2	MCF10A-GM_7	504	0.0294	832.0	168.3	20016	537.9	0.0261	0.00328	0.9210

|<
<<
Previous
Page 11 of 67
Next
>>
>
251 to 275 of 1656 records
per page:

HMS LINCS Project

LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Repeat performed by Scientist B in 2019 to assess reproducibility. Dataset 1 of 2: Normalized growth rate inhibition values. - Dataset (ID:20359)